



Three commonly missed pancreatic pathologies that are NOT simple neuroendocrine tumours



Anthony Gill MD FRCPA

Professor of Surgical Pathology

University of Sydney

&

Senior Staff Specialist Pathologist

Royal North Shore Hospital

Glucagon Cell Adenomatosis

Mahvash syndrome
Glucagon cell hyperplasia and neoplasia
Pancreatic alpha cell hyperplasia

Glucagon Cell Adenomatosis

Mahvash syndrome
Glucagon cell hyperplasia and neoplasia
Pancreatic alpha cell hyperplasia

"New syndrome" – recognised as a distinct entity under the WHO 2017 classification

Glucagon cell adenomatosis


Primary pathology is germline autosomal recessive inactivation of GCGR (glucagon receptor gene)

As GCGR is dysfunctional – massive elevation of serum glucagon levels.

But no clinical syndrome due to hyperglucagonemia – paradoxically may suffer hypoglycemia


Glucagon cell adenomatosis

- Absence of GCGR causes a feedback loop which drives massive glucagon cell hyperplasia -> Neoplasia
- Symptoms due to multiple pancreatic tumours, direct effect of glucagon (calcificatoin),









































Glucagon




Glucagon




Glucagon







Insulin




Insulin





Pancreatic Polypeptide





Somatostatin














Glucagon cell adenomatosis

Clinical features

- Massive hyperglucagonemia
- However, no symptoms due to hyperglucagonomemia in fact may develop hypoglycemia


Pathological features


- Multiple (sometimes hundreds) of glucagon producing tumours
- Arise in a background of alpha-cellhyperplasia progressing to neoplasia
- Glucagon IHC is definitive (panc polypeptide may also be produced)
- Although metastasis occurs commonly, ki67 index is very low

Glucagon cell adenomatosis



Consider whenever multiple glucagon producing tumours or widespread hyperplasia and not MEN1







Acinar Cell Carcinoma


2% of ICGC pancreatic cancer cases
Commonly presents as a tumour which
looks like a NET but is negative for
chromogrannin


MICROSCOPIC FEATURES


- Solid to trebecular arrangement of cells with acinar formation.
- The cells have abundant eosinophilic cytoplam, round to oval nuclei and prominent nucleoli.
- Not much pleomorphism.
- Infitrative borders.
- Rare mitoses

































Filamentous inclusions












BCL10 and trypsin immunohistochemisry




BCL10 and trypsin immunohistochemisry



FROZEN SECTION





Pancreatic Acinar cell Carcinoma

Incidence: varies in the literature, ranging between 1 to 13%
 -At present 1 to 2%

Age: more common during 5th through 7th decade

- Symptoms
- Most common: weight loss, abdominal pain and nausea and vomiting.
- "Lipase hypersecretion syndrome": Subcutaneous fat necrosis or panniculitis as a result of increase levels of lipase (10-15%)
- Syndrome-polyarthritis, subcutaneous fat necrosis, or panniculitis and eosinophilia

MOLECULAR GENETICS

- KRAS, p53, SMAD4, CDKN2A mutations very rare.
- 25% have beta-catenin/APC loss and may show abnormal nuclear staining for beta-catenin

Outcome

Poor prognosis but still better than stage matched pancreatic cancer

Not graded

5 year survival 25-50%

Patients with elevated levels of serum lipase had worse prognosis (hepatic metastasis)


VARIANTS

Acinar cell cystadenoma

Acinar cell cystadenocarcinoma

Mixed acinar cell carcinoma (mixed-ductal; mixed acinar-neuroendocrine)

Acinar cell carcinoma




Best markers are BCL10 and Trypsin Looks like a PNET but negative for chromogranin

Traps are:


May be mixed (MiNEN)


May have nuclear beta-catenin staining





Pancreatoblastoma


0.5% of ICGC pancreatic cancer cases
May show trilineage differentiation
(squamous, NET, acinar)

























































Outcome

Outcome is better than pancreatic cancer, 5year survival for resected patients 50-65%

Children may have better outcome than adults


Cases reported in association with Beckwith-Widemann syndrome and FAP

Pancreatoblastoma



Clues are squamous morules Mosaic beta-catenin pattern is key!!

Traps are:
Not all morules obvious
Trilineage expression (nets,acinar)



Three commonly missed pancreatic pathologies that are NOT simple neuroendocrine tumours

Glucagon cell adenomatosis (germline glucagon receptor mutation)


Pancreatic acinar cell carcinoma


Pancreatoblastoma

Glucagon cell adenomatosis




Consider whenever multiple glucagon producing tumours or widespread hyperplasia and not MEN1





Acinar cell carcinoma




Best markers are BCL10 and Trypsin Looks like a PNET but negative for chromogranin


Traps are:

May be mixed (MiNEN)

May have nuclear beta-catenin staining



Pancreatoblastoma



Clues are squamous morules (beta-catenin pos)

Traps are:

Not all morules obvious

Trilineage expression (nets,acinar)

